FDA Grants Orphan Drug and Rare Pediatric Disease Designations to Grünenthal’s Tegacorat for Duchenne Muscular Dystrophy Treatment

Earlier Intervention May Improve Motor Function in Duchenne Muscular Dystrophy

Researchers at Binghamton University, State University of New York were among the first to find ways to help patients of Duchenne muscular dystrophy (DMD), with the development of an effective drug. A new study suggests earlier use of this FDA-approved therapy may improve outcomes.

Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy

SEGRAM aims to offer an alternative to glucocorticoid‑based treatment

FDA Grants Orphan Drug and Rare Pediatric Disease Designations to Grünenthal’s Tegacorat for Duchenne Muscular Dystrophy Treatment

Aachen, 08 July 2026 – Grünenthal, a global leader in pain management and related diseases, announced today that their investigational compound tegacorat (GRM-01) has received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD). Tegacorat, a non-steroidal Selective Glucocorticoid Receptor Agonist... Source